Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Animal Health Market Intelligence Report 2026-2034 Featuring Strategic Analysis of Bayer, Elanco, Merck, Merial, Zoetis, Boehringer Ingelheim, Ceva Sante Animale, Heska and More

globenewswire.com
ELAN Elanco's launch of ZenreliaT for canine skin disease management and its acquisition of Bayer's aqua business are highlighted as positive developments, indicating innovation and strategic expansion within the growing animal health market. MRK Merck is identified as a leading innovator in veterinary drugs, diagnostics, and telemedicine. Its acquisition of Elanco's aqua business further solidifies its strategic position and expansion in the animal health sector. ZTS Zoetis is recognized as a leading company innovating in veterinary drugs, diagnostics, and telemedicine, contributing to the overall growth and positive outlook of the animal health market.

Animal Health Market Intelligence Report 2026-2034 Featuring Strategic Analysis of Bayer, Elanco, Merck, Merial, Zoetis, Boehringer Ingelheim, Ceva Sante Animale, Heska and More Dublin, April 15, 2026 (GLOBE NEWSWIRE) -- The "Animal Health Market Size, Share, Trends and Forecast by Animal Type, Product Type, and Region, 2026-2034" has been added to ResearchAndMarkets.com's offering.

The global animal health market, valued at USD 40.1 billion in 2025, is projected to reach USD 51.6 billion by 2034, growing at a CAGR of 2.73% from 2026 to 2034. North America held a dominant market share of 44.9% in 2025, driven by an increasing number of pet owners seeking high-quality veterinary care and advanced technologies.

Key market drivers include heightened awareness of zoonotic diseases and technological advancements in vaccines, diagnostics, and antimicrobial therapies. Governments and public health campaigns emphasize preventive measures to control zoonotic infections. The livestock industry is enhancing biosecurity for food safety, while pharmaceutical companies focus on innovative treatments.

In the U.S., the demand for canine dermatology treatments is rising due to pet adoption and awareness of skin disorders. Companies are developing targeted therapies, exemplified by Elanco's launch of ZenreliaT (ilunocitinib tablets) in 2024, for canine skin disease management. Veterinary dermatologists are adopting precision medicine approaches, supported by the expansion of telemedicine and advanced diagnostics, driving market growth.

Market Trends:

Market Segmentation:

Regional Insights:

Top Industry Players:

Leading companies such as Bayer, Elanco, Merck, and Zoetis are innovating in veterinary drugs, diagnostics, and telemedicine. Merck's acquisition of Elanco's aqua business exemplifies strategic expansion in the animal health sector, ensuring the production of essential veterinary products and services.

Key Questions Addressed in the Report:

Key Attributes

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/yh56u3

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment